Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 28 July 2006
Lentivector licensing agreement with
Biogen Idec
Oxford BioMedica has entered into an agreement to license its LentiVector technology to Biogen Idec for use in research activities
Oxford BioMedica will receive an upfront licence payment and an annual maintenance fee Further financial details were not disclosed
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
LentiVector, a lentivirus-based system, is one of the most powerful technologies available for gene delivery to a wide range of cell and tissue types.
The technology has applications both in therapeutic products and drug discovery, as a tool for target validation and the creation of targeted disease models.
It has also been shown to enhance the efficiency of developing transgenic birds and mammals.
Oxford BioMedica has a comprehensive portfolio of US and European patents covering the LentiVector technology.
Oxford BioMedica's senior vice president commercial development, Peter Nolan, said: "We are delighted to add Biogen Idec to our list of licencees for the LentiVector technology".
"This agreement is a further demonstration of the technology's superiority and broad utility".
"We expect Oxford BioMedica's LentiVector technology to become the system of choice for safe and effective gene delivery in drug discovery and transgenics.".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
